RPE65

The RPE65 gene tells cells how to build an enzyme called retinoid isomerohydrolase, which works inside the retinal pigment epithelium, a support layer behind the light-sensing cells (photoreceptors) of the retina. This enzyme performs an essential step in the visual cycle by converting a form of vitamin A into 11-cis retinol, a precursor to the molecule that photoreceptors need to respond to light. When RPE65 does not work properly, this recycling step breaks down and the photoreceptors cannot function normally, which leads to vision loss. Most disease-causing RPE65 changes are inherited in an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) pattern, meaning a person is affected when both inherited copies of the gene carry a variant. Rare autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) forms exist, in which a single altered copy is enough to cause a distinct, generally later-onset condition affecting the central retina. You may see RPE65-related disease referred to by names such as LCA2 or RP20, which are older labels for these conditions.

RPE65-related disease most often causes severe, early vision problems, with night blindness and reduced vision beginning in infancy or early childhood. In studies of affected people, common findings include severely reduced visual acuity, narrowing of the visual field, and greatly diminished electrical responses of the retina on testing. Pigmentary changes of the peripheral retina are a consistent feature reported across patient series, while features such as narrowing of retinal blood vessels, optic disc paleness, and the appearance of the central macula vary more from person to person. The severity is not the same for everyone, and researchers have described a spectrum ranging from severe early-onset disease to milder, more slowly progressive forms. At the milder end, some people have mostly preserved cone (daytime and color) function with only slightly impaired rod (night vision) function, and rare presentations resemble congenital stationary night blindness or fundus albipunctatus. In one large cohort, rare individuals retained relatively good visual acuity and well-preserved visual fields, underscoring how variable the condition can be even within the same disease. The rare dominant forms tend to appear later in adulthood as a macular (central retina) dystrophy rather than the widespread early disease seen in the recessive forms.

The role of RPE65 in the visual cycle is well understood, and its link to early-onset inherited retinal disease is firmly established in the medical literature. Across patient cohorts in Germany, Brazil, and India, biallelic RPE65 variants were repeatedly identified as a cause of Leber congenital amaurosis, early-onset severe retinal dystrophy, and retinitis pigmentosa. RPE65 is a recognized but relatively uncommon cause of these conditions, and how often it appears varies across populations and referral centers. Voretigene neparvovec-rzyl (Luxturna) is an approved gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) that delivers a working copy of RPE65 to retinal cells through a subretinal injection, and it is intended for people with disease caused by variants in both copies of the gene. This therapy began with animal studies and then human trials showing that supplying a normal copy of RPE65 could improve visual function, and it became the first gene therapy approved for a genetic disease of this kind. Real-world experience and reviews report functional improvements consistent with the original trial results, and evidence suggests that people with more preserved photoreceptors before treatment, including many children, have the greatest potential to benefit.

Even for people who share RPE65-related disease, it is not possible to predict exactly when symptoms will begin or how quickly vision will change, because the condition varies between and within families. Responses to the approved gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) have also been variable and not always long-lasting, and there is no firm consensus yet on which patient characteristics best predict a good outcome or define eligibility. One review notes that no single upper limit of retinal degeneration has been established as the deciding factor for who may respond. The rare autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) RPE65 forms are still being characterized; a founder variant of Flemish origin, p.(E519K), was described in a large group of affected individuals only recently, and these dominant forms do not respond to the approved gene-replacement therapy because their underlying mechanism differs. Some newer approaches, such as prime-editing strategies, exist only in laboratory or cell-based research and are not treatments.

As of the date of this review, voretigene neparvovec-rzyl (Luxturna) is an approved gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) for inherited retinal dystrophy caused by variants in both copies of RPE65, delivered by a surgical injection under the retina. It introduces a working copy of the gene to retinal cells so they can resume part of their normal function, and it is generally offered to people who still have viable photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cells. Beyond this approved therapy, additional RPE65 gene-replacement products are being tested in clinical trials, and researchers are also studying broader strategies such as neuroprotection and stem cell approaches that are not specific to RPE65 and remain investigational. An oral vitamin A-derivative drug, QLT091001, was tested in completed early-phase trials for RPE65- and LRAT-related disease, but these records do not establish it as an approved treatment. A combined gene-replacement plus anti-cell-death approach improved and better sustained retinal protection in a mouse model of RPE65 disease, which is laboratory research and not an available treatment.

• A newly described dominant RPE65 variant

  Large genotype-phenotype cohort study with laboratory analysis.

  What was found:

  The single-copy variant was found in 83 affected individuals of European ancestry, lowered RPE65 activity and stability, and caused a late-onset, mainly central (macular) dystrophy inherited in a dominant pattern.

  Why it matters:

  It expands understanding of rare dominant RPE65 disease, which differs in outlook and does not respond to the approved gene-replacement therapy.

  Limitation: The variant is rare and specific to a founder population, and dominant forms remain less well understood than recessive ones.

• Treating RPE65 disease: how the first approved retinal gene therapy came to be

  Review and clinical perspective on treatment.

  What was found:

  Subretinal injection of the AAV-delivered RPE65 gene reversed blindness first in animal models and then in humans, leading to the first regulatory-approved gene therapy for a genetic disease.

  Why it matters:

  It documents that a gene-specific, approved treatment exists for biallelic RPE65 disease and explains practical considerations for its use.

  Limitation: It is a narrative review rather than a new controlled study, and it does not resolve who benefits most or how durable the effect is.

• Who may be a candidate for RPE65 gene therapy

  Scoping review of existing literature.

  What was found:

  Functional improvements after treatment were consistent with trial results, but no consensus on eligibility exists; preserved photoreceptors before treatment, common in children, were linked to greater potential benefit.

  Why it matters:

  It highlights that outcomes depend heavily on the state of the retina at the time of treatment, which is central to counseling.

  Limitation: Pre-treatment characteristics and outcomes were not reported consistently across the studies reviewed.

• Milder RPE65-associated retinal disease

  Small case series with detailed diagnostics.

  What was found:

  Both had only slightly impaired rod (night vision) function with largely preserved cone function, consistent with variants that allow partial enzyme activity; early localized rod changes were a hallmark.

  Why it matters:

  It shows RPE65 disease is a spectrum, not a single severe condition, which affects monitoring and counseling.

  Limitation: Only two patients were studied, so findings may not generalize.

• RPE65 variants in an inherited retinal disease clinic in Brazil

  Single-center observational case series.

  What was found:

  RPE65 variants were found in seven patients, spanning LCA, early-onset severe retinal dystrophy, and RP, with visual loss onset ranging from birth to the third decade and consistent peripheral pigmentary changes.

  Why it matters:

  It illustrates the range of diagnoses and ages of onset linked to RPE65 in a real-world clinic.

  Limitation: Small numbers from one center limit how broadly the frequency and patterns apply.

RPE65-related disease often begins in infancy or early childhood, so early diagnosis matters for planning developmental, educational, and vision support and for timely discussion of therapy while more photoreceptors may still be preserved. Because the common forms are recessive, both parents are typically unaffected carriers, and relatives may wish to discuss what this inheritance pattern means for them with a genetic counselor. The rarer dominant forms can appear later in adulthood, so a family history of central vision loss may be relevant information to share with clinicians.

• Do my RPE65 variants affect both copies of the gene (recessive) or one copy (dominant), and what does that mean for my options?
• What do my retinal imaging and functional tests show about how much of my retina is still preserved?
• Is the approved RPE65 gene therapy something my situation should be evaluated for, and where is that assessment done?
• How often should my vision and retina be monitored given how variable this condition can be?
• Are there natural history studies or registries I could consider participating in?
• What should other family members know about testing, given how RPE65 disease is inherited?

Confirming the specific RPE65 variants and whether they affect one or both copies of the gene is an important step, because the recessive and dominant forms differ in outlook and in potential for treatment. Detailed retinal testing, including imaging and measures of rod and cone function, can help document the current condition of the retina and guide monitoring and counseling. A retinal specialist or genetic counselor can explain how these results apply to your particular situation and discuss whether gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) may be relevant.